These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37144893)

  • 1. Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scores.
    Dewilde S; Janssen MF; Tollenaar NH; Vanoli F; Frangiamore R; Phillips G; Paci S; Mantegazza R; Meisel A; Stascheit F
    Muscle Nerve; 2023 Jul; 68(1):65-72. PubMed ID: 37144893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician- and self-assessed myasthenia gravis activities of daily living score.
    Lee HL; Min JH; Seok JM; Cho EB; Cho HJ; Kim YD; Kim BJ
    Muscle Nerve; 2018 Mar; 57(3):419-422. PubMed ID: 28796382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
    Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT;
    Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychometric properties of MG-ADL items and MG-ADL score: An assessment of distributional characteristics, validity and factor structure in two large datasets.
    Janssen MF; Dewilde S; Wolfe GI; Muppidi S; Phillips G
    J Neurol Sci; 2024 Aug; 463():123135. PubMed ID: 39068745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
    Gratton SM; Herro AM; Feuer WJ; Lam BL
    J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients.
    Raggi A; Antozzi C; Baggi F; Leonardi M; Maggi L; Mantegazza R
    Neurol Sci; 2017 Nov; 38(11):1927-1931. PubMed ID: 28780706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translation and validation of the arabic version of the myasthenia gravis activities of daily living scale.
    Alanazy MH; Abuzinadah AR; Muayqil T
    Muscle Nerve; 2019 May; 59(5):583-586. PubMed ID: 30697753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.
    McPherson T; Aban I; Duda PW; Farzaneh-Far R; Wolfe GI; Kaminski HJ; Cutter G; Lee I;
    Muscle Nerve; 2020 Aug; 62(2):261-266. PubMed ID: 32369631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The myasthenia gravis--specific activities of daily living profile.
    Muppidi S
    Ann N Y Acad Sci; 2012 Dec; 1274():114-9. PubMed ID: 23252905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of MG-ADL in myasthenia gravis clinical research and care.
    Muppidi S; Silvestri NJ; Tan R; Riggs K; Leighton T; Phillips GA
    Muscle Nerve; 2022 Jun; 65(6):630-639. PubMed ID: 34989427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the Adverse Event Unit (AEU).
    Hehir MK; Conaway M; St Sauveur AB; Feb K; Kolb NA; Waheed W; McNeish BL; Tweedy N; Burns TM
    Muscle Nerve; 2024 Jan; 69(1):32-39. PubMed ID: 37676119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of MG-ADL for generalized weakness in myasthenia gravis.
    de Meel RHP; Raadsheer WF; van Zwet EW; Verschuuren JJGM; Tannemaat MR
    Eur J Neurol; 2019 Jun; 26(6):947-950. PubMed ID: 30417962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Myasthenia Gravis-specific Activities of Daily Living scale as a useful outcome measure and in routine clinical management in Polish patients.
    Rozmilowska IM; Adamczyk-Sowa MH; Czyzewski D
    Neurol Neurochir Pol; 2018; 52(3):368-373. PubMed ID: 29370887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depression: A Contributing Factor to the Clinical Course in Myasthenia Gravis Patients.
    Mihalache OA; Vilciu C; Petrescu DM; Petrescu C; Manea MC; Ciobanu AM; Ciobanu CA; Popa-Velea O; Riga S
    Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256317
    [No Abstract]   [Full Text] [Related]  

  • 17. Reliability and Validity of Turkish Myasthenia Gravis-Activities of Daily Living Scale.
    Karanfil E; Salcı Y; Fil-Balkan A; Bekircan-Kurt CE; Erdem Özdamar S; Armutlu K
    OTJR (Thorofare N J); 2021 Apr; 41(2):101-107. PubMed ID: 33016212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness: a real-world study of patients in the US and five European countries.
    Pesa J; Choudhry Z; de Courcy J; Barlow S; Gibson G; Chatterton E; Birija SL; Hahn B; Govindarajan R
    BMC Neurol; 2024 Oct; 24(1):385. PubMed ID: 39395956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MG-ADL: still a relevant outcome measure.
    Muppidi S; Wolfe GI; Conaway M; Burns TM;
    Muscle Nerve; 2011 Nov; 44(5):727-31. PubMed ID: 22006686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translation and validation of the Myasthenia Gravis Activities of Daily Living Questionnaire: Latvian version.
    Grosmane A; Roze I; Roddate M; Ķauķe G; Žukova V; Glāzere I; Zolovs M; Ķēniņa V
    Front Neurol; 2024; 15():1397603. PubMed ID: 38859974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.